2020•PubMedRequires access

[The value of serum abnormal prothrombin in clinical application of hepatocellular carcinoma].

J W Zhang, Lu Guan, Eunyoung Cho, Jin-Yong Yang, W Xuan, Z H Meng, W Li

Abstract

PIVKA-Ⅱ can be used as a serological marker for HCC screening and diagnosis. In particular, PIVKA-Ⅱ detection was significantly sensitive than AFP in the earlier stage of HCC. Combined detection of PIVKA-Ⅱ and AFP can effectively improve the diagnostic rate of HCC in all stages. The significant elevation of PIVKA-Ⅱ is also helpful to determine the tumor aggressiveness, vascular invasion and prognosis of HCC patients.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Medicine, Hepatocellular carcinoma, Internal medicine, Gastroenterology, HBsAg, Vitamin K antagonist, Hepatitis B virus, Immunology